Your browser is no longer supported. Please, upgrade your browser.
AGLE [NASD]
Aeglea BioTherapeutics, Inc.
Index- P/E- EPS (ttm)-1.27 Insider Own1.20% Shs Outstand49.31M Perf Week-7.64%
Market Cap196.83M Forward P/E- EPS next Y-0.97 Insider Trans98.67% Shs Float48.55M Perf Month-7.21%
Income-68.10M PEG- EPS next Q-0.29 Inst Own92.60% Short Float1.69% Perf Quarter-46.51%
Sales15.10M P/S13.03 EPS this Y38.10% Inst Trans1.08% Short Ratio2.39 Perf Half Y-36.46%
Book/sh2.07 P/B1.93 EPS next Y1.00% ROA-45.30% Target Price13.62 Perf Year-40.98%
Cash/sh2.28 P/C1.75 EPS next 5Y- ROE-56.20% 52W Range3.47 - 8.79 Perf YTD-16.00%
Dividend- P/FCF- EPS past 5Y-8.50% ROI- 52W High-54.61% Beta1.44
Dividend %- Quick Ratio5.80 Sales past 5Y- Gross Margin- 52W Low14.99% ATR0.30
Employees90 Current Ratio5.80 Sales Q/Q- Oper. Margin- RSI (14)37.63 Volatility6.58% 6.86%
OptionableYes Debt/Eq0.00 EPS Q/Q-42.20% Profit Margin- Rel Volume0.55 Prev Close4.20
ShortableYes LT Debt/Eq0.00 EarningsNov 04 BMO Payout- Avg Volume344.38K Price3.99
Recom2.10 SMA20-9.52% SMA50-17.34% SMA200-39.64% Volume187,974 Change-5.00%
May-04-20Initiated Piper Sandler Overweight $12
Mar-21-19Initiated JP Morgan Overweight $14
Sep-04-18Downgrade Wells Fargo Outperform → Market Perform
Apr-24-18Initiated Evercore ISI Outperform $37
Mar-14-18Reiterated Needham Buy $8 → $12
Jan-25-22 08:01AM  
Jan-05-22 07:01AM  
Dec-17-21 06:14AM  
Dec-14-21 09:15AM  
Dec-12-21 06:18AM  
Dec-06-21 01:01PM  
07:18AM  
06:30AM  
Dec-05-21 06:00PM  
Nov-16-21 07:01AM  
Nov-04-21 08:55AM  
07:01AM  
06:59AM  
Oct-19-21 06:26AM  
Sep-01-21 08:30AM  
Aug-10-21 01:00AM  
Aug-08-21 03:06AM  
Aug-07-21 03:14AM  
Aug-05-21 10:05AM  
08:30AM  
Jul-26-21 11:50AM  
Jul-15-21 08:30AM  
Jul-14-21 04:30PM  
Jul-08-21 08:30AM  
Jun-24-21 08:30AM  
Jun-22-21 08:30AM  
May-10-21 08:30AM  
May-06-21 08:30AM  
May-03-21 08:30AM  
Apr-01-21 04:30PM  
Mar-22-21 08:30AM  
Mar-18-21 08:30AM  
Feb-24-21 04:30PM  
Feb-18-21 01:45AM  
Feb-08-21 10:11AM  
Feb-03-21 04:30PM  
Jan-04-21 04:30PM  
Dec-30-20 12:00PM  
Dec-18-20 08:28PM  
Dec-17-20 04:05PM  
Dec-01-20 07:30AM  
Nov-24-20 04:40PM  
Nov-17-20 04:30PM  
Nov-10-20 05:40AM  
Nov-05-20 08:30AM  
Nov-03-20 08:44AM  
Oct-26-20 08:30AM  
Oct-13-20 12:35PM  
Oct-05-20 04:30PM  
Sep-11-20 06:39AM  
Sep-02-20 04:05PM  
Aug-25-20 08:40AM  
Aug-18-20 04:05PM  
Aug-10-20 08:30AM  
Jul-13-20 09:28AM  
Jun-30-20 11:25PM  
Jun-29-20 12:00PM  
Jun-26-20 11:30AM  
Jun-23-20 08:47AM  
Jun-10-20 11:30AM  
Jun-08-20 09:03AM  
Jun-04-20 11:17AM  
Jun-01-20 04:05PM  
May-29-20 11:49AM  
May-28-20 04:10PM  
May-27-20 08:43AM  
May-26-20 08:30AM  
May-21-20 11:30AM  
May-20-20 08:56AM  
May-19-20 07:26PM  
10:10AM  
08:30AM  
May-07-20 08:41AM  
08:30AM  
May-06-20 09:31AM  
06:19AM  
May-05-20 12:00PM  
Apr-30-20 04:05PM  
Apr-28-20 09:07AM  
Apr-27-20 04:01PM  
Apr-08-20 07:30AM  
Mar-29-20 08:31AM  
Feb-24-20 07:30AM  
Feb-13-20 05:37AM  
Jan-13-20 07:00AM  
Jan-08-20 05:11AM  
Jan-06-20 04:05PM  
Dec-12-19 07:08PM  
Dec-03-19 05:22AM  
Nov-26-19 08:30AM  
Nov-06-19 08:30AM  
Nov-04-19 08:30AM  
Oct-10-19 08:54AM  
Sep-04-19 11:22AM  
Sep-03-19 06:00AM  
Aug-29-19 08:30AM  
Aug-06-19 08:00AM  
Jul-25-19 07:21AM  
Jul-24-19 04:05PM  
Jul-17-19 03:47PM  
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes cystinuria and research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shanafelt ArmenDirectorDec 13Buy3.6514,68553,600150,000Dec 13 08:41 PM
Shanafelt ArmenDirectorDec 10Buy3.6513,51649,333135,315Dec 13 08:41 PM
Quinn Anthony G.President & CEODec 10Buy3.7510,52639,472328,795Dec 13 08:39 PM
Shanafelt ArmenDirectorDec 09Buy3.67121,799446,759121,799Dec 13 08:41 PM
Quinn Anthony G.President & CEODec 09Buy3.7043,108159,500318,269Dec 13 08:39 PM
Alspaugh JonathanChief Financial OfficerDec 09Buy3.7250,000186,00090,372Dec 13 08:37 PM
Alspaugh JonathanChief Financial OfficerAug 18Buy6.727,20048,40040,372Aug 18 05:21 PM
Alspaugh JonathanChief Financial OfficerAug 17Buy6.5023,392151,98533,172Aug 18 05:21 PM
Alspaugh JonathanChief Financial OfficerAug 16Buy6.379,78062,2759,780Aug 18 05:21 PM